
RealRate

PHARMACEUTICAL 2018

LIXTE BIOTECHNOLOGY HOLDINGS INC.

Rank 313 of 349



RealRate

PHARMACEUTICAL 2018

LIXTE BIOTECHNOLOGY HOLDINGS INC.

Rank 313 of 349

The relative strengths and weaknesses of LIXTE BIOTECHNOLOGY HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIXTE BIOTECHNOLOGY HOLDINGS INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 88% points. The greatest weakness of LIXTE BIOTECHNOLOGY HOLDINGS INC. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 423% points.

The company's Economic Capital Ratio, given in the ranking table, is -718%, being 440% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	1,368
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	373
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1.4
Property and Equipment	0
Research and Development	467
Revenues	0
Selling, General and Administrative Expense	1,343

Output Variable	Value in 1000 USD
Assets	1,368
Liabilities	373
Expenses	1,810
Stockholders Equity	995
Net Income	-1,808
Comprehensive Net Income	-1,808
Economic Capital Ratio	-718%